Sanofi (SNY) and Earendil Labs have signed a licensing deal for two bispecific antibodies that target autoimmune and inflammatory bowel diseases, Earendil Labs said in a statement Thursday.
Sanofi will gain exclusive global rights to drug candidates HXN-1002 and HXN-1003 once the deal closes, according to the statement.
Earendil will receive an upfront payment of $125 million from Sanofi, it added.
Earendil could earn up to $1.72 billion in development and commercial milestones, including a $50 million payment expected soon after closing, Earendil Labs said.
Earendil is also eligible for tiered sales royalties that start in the high single digits and rise to the low double digits, the statement added.
Sanofi's shares were up about 1.6% in recent trading.
Price: 51.35, Change: +0.79, Percent Change: +1.56
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。